|
1
|
Horwich A, Parker C and Kataja V: Prostate
cancer: ESMO clinical recommendations for diagnosis, treatment and
follow-up. Ann Oncol. 20(Suppl 4): S76–S78. 2009. View Article : Google Scholar
|
|
2
|
Armstrong AJ and Febbo PG: Using surrogate
biomarkers to predict clinical benefit in men with
castration-resistant prostate cancer: an update and review of the
literature. Oncologist. 14:816–827. 2009.PubMed/NCBI
|
|
3
|
Deng B, Zhang S, Miao Y, et al:
Adrenomedullin expression in epithelial ovarian cancers and
promotes HO8910 cell migration associated with upregulating
integrin alpha5beta1 and phosphorylating FAK and paxillin. J Exp
Clin Cancer Res. 31:192012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang X, Nakamura M, Mori I, et al:
Calcitonin receptor gene and breast cancer: quantitative analysis
with laser capture microdissection. Breast Cancer Res Treat.
83:109–117. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Delis S, Bakoyiannis A, Giannakou N,
Tsigka A, Avgerinos C and Dervenis C: Asymptomatic
calcitonin-secreting tumor of the pancreas. A case report. JOP.
7:70–73. 2006.PubMed/NCBI
|
|
6
|
Ferrigno D, Buccheri G and Biggi A: Serum
tumour markers in lung cancer: history, biology and clinical
applications. Eur Respir J. 7:186–197. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shah GV, Noble MJ, Austenfeld M, Weigel J,
Deftos LJ and Mebust WK: Presence of calcitonin-like
immunoreactivity (iCT) in human prostate gland: evidence for iCT
secretion by cultured prostate cells. Prostate. 21:87–97. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomas S, Chigurupati S, Anbalagan M and
Shah G: Calcitonin increases tumorigenicity of prostate cancer
cells: evidence for the role of protein kinase A and urokinase-type
plasminogen receptor. Mol Endocrinol. 20:1894–1911. 2006.
View Article : Google Scholar
|
|
9
|
Chien J, Ren Y, Qing Wang Y, et al:
Calcitonin is a prostate epithelium-derived growth stimulatory
peptide. Mol Cell Endocrinol. 181:69–79. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Conner AC, Simms J, Hay DL, et al:
Heterodimers and family-B GPCRs: RAMPs, CGRP and adrenomedullin.
Biochem Soc Trans. 32:843–846. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Purdue BW, Tilakaratne N and Sexton PM:
Molecular pharmacology of the calcitonin receptor. Receptors
Channels. 8:243–255. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tolcos M, Tikellis C, Rees S, Cooper M and
Wookey P: Ontogeny of calcitonin receptor mRNA and protein in the
developing central nervous system of the rat. J Comp Neurol.
456:29–38. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wookey PJ, McLean CA, Hwang P, et al: The
expression of calcitonin receptor detected in malignant cells of
the brain tumour glioblastoma multiforme and functional properties
in the cell line A172. Histopathology. 60:895–910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shah GV, Thomas S, Muralidharan A, et al:
Calcitonin promotes in vivo metastasis of prostate cancer cells by
altering cell signaling, adhesion, and inflammatory pathways.
Endocr Relat Cancer. 15:953–964. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chigurupati S, Kulkarni T, Thomas S and
Shah G: Calcitonin stimulates multiple stages of angiogenesis by
directly acting on endothelial cells. Cancer Res. 65:8519–8529.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jackel MC, Mitteldorf C, Schweyer S and
Fuzesi L: Clinical relevance of Fas (APO-1/CD95) expression in
laryngeal squamous cell carcinoma. Head Neck. 23:646–652. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shah GV, Muralidharan A, Gokulgandhi M,
Soan K and Thomas S: Cadherin switching and activation of β-catenin
signaling underlie proinvasive actions of calcitonin-calcitonin
receptor axis in prostate cancer. J Biol Chem. 284:1018–1030.
2009.
|
|
18
|
Brawer MK: Prostatic intraepithelial
neoplasia: an overview. Rev Urol. 7(Suppl 3): S11–S18. 2005.
|
|
19
|
Thomas S and Shah G: Calcitonin induces
apoptosis resistance in prostate cancer cell lines against
cytotoxic drugs via the Akt/survivin pathway. Cancer Biol Ther.
4:1226–1233. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ritchie CK, Thomas KG, Andrews LR, Tindall
DJ and Fitzpatrick LA: Effects of the calciotrophic peptides
calcitonin and parathyroid hormone on prostate cancer growth and
chemotaxis. Prostate. 30:183–187. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shah GV, Rayford W, Noble MJ, et al:
Calcitonin stimulates growth of human prostate cancer cells through
receptor-mediated increase in cyclic adenosine 3′,5′-monophosphates
and cytoplasmic Ca2+ transients. Endocrinology.
134:596–602. 1994.PubMed/NCBI
|
|
22
|
Goodman MT, Ferrell R, McDuffie K, et al:
Calcitonin gene polymorphism CALCA-624 (T/C) and ovarian cancer.
Environ Mol Mutagen. 46:53–58. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Trimboli P, Rossi F, Baldelli R, et al:
Measuring calcitonin in washout of the needle in patients
undergoing fine needle aspiration with suspicious medullary thyroid
cancer. Diagn Cytopathol. 40:394–398. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hebden C, Smalt R, Chambers T and Pondel
MD: Multiple promoters regulate human calcitonin receptor gene
expression. Biochem Biophys Res Commun. 272:738–743. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Silverman AL, Park JG, Hamilton SR, Gazdar
AF, Luk GD and Baylin SB: Abnormal methylation of the calcitonin
gene in human colonic neoplasms. Cancer Res. 49:3468–3473.
1989.PubMed/NCBI
|
|
26
|
Shah GV: Calcitonin. Encyclopedia of
Cancer. 2:16–20. 2009.
|
|
27
|
Yigitbasi O, Ozturk U, Goktug HN, Gucuk A
and Bakirtas H: Prognostic factors in metastatic prostate cancer.
Urol Oncol. 29:162–165. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Andren O, Fall K, Franzen L, Andersson SO,
Johansson JE and Rubin MA: How well does the Gleason score predict
prostate cancer death? A 20-year followup of a population based
cohort in Sweden. J Urol. 175:1337–1340. 2006.PubMed/NCBI
|
|
29
|
Masieri L, Lanciotti M, Gontero P, et al:
The prognostic role of preoperative chromogranin A expression in
prostate cancer after radical prostatectomy. Arch Ital Urol Androl.
84:17–21. 2012.PubMed/NCBI
|
|
30
|
Gao J, Arnold JT and Isaacs JT: Conversion
from a paracrine to an autocrine mechanism of androgen-stimulated
growth during malignant transformation of prostatic epithelial
cells. Cancer Res. 61:5038–5044. 2001.
|
